Research programme: stem cell therapeutics - BioRestorative Therapies

Drug Profile

Research programme: stem cell therapeutics - BioRestorative Therapies

Alternative Names: BRTX-100; brtxDISC; ThermoStem

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioRestorative Therapies
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Diabetes mellitus; Hypertension; Intervertebral disc degeneration; Metabolic disorders; Obesity

Most Recent Events

  • 11 Jun 2018 BRTX 100 is available for licensing as of 11 Jun 2018.
  • 17 Oct 2017 BioRestorative receives a Notice of Allowance related to ThermoStem® programme in Japan
  • 20 Apr 2017 BioRestorative Therapies has patents pending for covering methods related to methods of generating stem cells and stem cell lines from brown adipose tissue in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top